破发股盟科药业2发起人股东拟询价转让 上市后连亏3年

Core Viewpoint - The company Mengke Pharmaceutical (688373.SH) has announced a share transfer plan involving major shareholders JSR Limited and Best Idea International Limited, with a total of 22,946,192 shares to be transferred, representing 3.50% of the company's total equity [1] Group 1: Share Transfer Details - The share transfer is a non-public transfer and will not occur through centralized bidding or block trading, thus not classified as a secondary market reduction [1] - The transferees must be institutional investors with appropriate pricing capabilities and risk tolerance [1] - The shares acquired through this transfer cannot be sold within six months after the transfer [1] Group 2: Shareholder Information - JSR Limited and Best Idea International Limited are the third and fourth largest shareholders of Mengke Pharmaceutical, respectively [1] - The top ten shareholders include Genie Pharma (10.92%), MicuRx (HK) Limited (10.79%), Best Idea International Limited (10.49%), and JSR Limited (5.88%) [2] Group 3: Financial Performance - Mengke Pharmaceutical has been publicly listed on the Shanghai Stock Exchange since August 5, 2022, with an initial public offering (IPO) price of 8.16 yuan per share [3] - The company has reported continuous losses for three and a half years, with revenues of 48.21 million yuan, 90.77 million yuan, and 130 million yuan from 2022 to 2024, and net losses of 220 million yuan, 421 million yuan, and 441 million yuan during the same period [4] - In the first half of 2025, the company reported a revenue of 66.97 million yuan, a year-on-year increase of 10.26%, but still a net loss of 139 million yuan [4]